What was the reported price per share for Pierre Legault’s Syndax (SNDX) stock award?

The Form 4 reports that Pierre Legault acquired 24,000 shares of Syndax Pharmaceuticals common stock at a price of $0 per share . This reflects a compensatory equity award, rather than an open-market purchase, and increased his total beneficial ownership to 114,000 shares.

Syndax (SNDX) director Pierre Legault awarded 24,000 RSUs, now holds 114,000 shares

Q: What insider transaction did Syndax Pharmaceuticals (SNDX) disclose for Pierre Legault?

Syndax Pharmaceuticals disclosed that director Pierre Legault received an equity award of 24,000 shares of common stock on February 4, 2026 . This stock award increased his directly held beneficial ownership to 114,000 shares following the reported transaction.

Q: How many Syndax Pharmaceuticals (SNDX) shares does Pierre Legault own after this Form 4?

After the reported transaction, director Pierre Legault beneficially owns 114,000 shares of Syndax Pharmaceuticals common stock. This figure reflects the addition of a 24,000-share stock award reported as acquired at a price of $0 per share .

Q: What type of equity award did Syndax Pharmaceuticals (SNDX) grant to Pierre Legault?

Pierre Legault received an award of Restricted Stock Units (RSUs) covering 24,000 shares of Syndax Pharmaceuticals common stock. According to the disclosure, these RSUs vest one year from the grant date and are subject to delivery and transfer restrictions.

Q: When do Pierre Legault’s Syndax (SNDX) restricted stock units vest?

The 24,000 restricted stock units granted to director Pierre Legault vest one year from the date of grant . The underlying shares are not delivered and cannot be transferred or sold until vesting and certain events such as separation from service or change in control.

Q: Are Pierre Legault’s new Syndax (SNDX) restricted stock units immediately tradable?

No, the 24,000 restricted stock units are not immediately tradable. The filing states the underlying shares will not be delivered and may not be transferred or sold until they vest and the earlier of separation from service, death, disability, or change in control.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Syndax Pharmaceuticals director receives equity award. Director Pierre Legault was granted 24,000 shares of Syndax Pharmaceuticals common stock on February 4, 2026 as a stock award priced at $0 per share, increasing his beneficial ownership to 114,000 shares held directly.

The award is in the form of restricted stock units that vest one year from the grant date. The underlying shares cannot be delivered, transferred, or sold until vesting and the earlier of separation from service, death, disability, or a change in control.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Legault Pierre

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	24,000	$0.00	--

Holdings After Transaction: Common Stock — 114,000 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/06/2026 - 04:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Legault Pierre

(Last)

(First)

(Middle)

C/O SYNDAX PHARMACEUTICALS, INC.

730 THIRD AVENUE, FLOOR 9

(Street)

NEW YORK

10017

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Syndax Pharmaceuticals Inc [ SNDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/04/2026		A		24,000⁽¹⁾	A	$0	114,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

	/s/ Michael A. Metzger, as Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Syndax Pharmaceuticals (SNDX) disclose for Pierre Legault?

Syndax Pharmaceuticals disclosed that director Pierre Legault received an equity award of 24,000 shares of common stock on February 4, 2026. This stock award increased his directly held beneficial ownership to 114,000 shares following the reported transaction.

How many Syndax Pharmaceuticals (SNDX) shares does Pierre Legault own after this Form 4?

After the reported transaction, director Pierre Legault beneficially owns 114,000 shares of Syndax Pharmaceuticals common stock. This figure reflects the addition of a 24,000-share stock award reported as acquired at a price of $0 per share.

What type of equity award did Syndax Pharmaceuticals (SNDX) grant to Pierre Legault?

Pierre Legault received an award of Restricted Stock Units (RSUs) covering 24,000 shares of Syndax Pharmaceuticals common stock. According to the disclosure, these RSUs vest one year from the grant date and are subject to delivery and transfer restrictions.

When do Pierre Legault’s Syndax (SNDX) restricted stock units vest?

The 24,000 restricted stock units granted to director Pierre Legault vest one year from the date of grant. The underlying shares are not delivered and cannot be transferred or sold until vesting and certain events such as separation from service or change in control.

Are Pierre Legault’s new Syndax (SNDX) restricted stock units immediately tradable?

No, the 24,000 restricted stock units are not immediately tradable. The filing states the underlying shares will not be delivered and may not be transferred or sold until they vest and the earlier of separation from service, death, disability, or change in control.